/ /

  • linkedin
  • Increase Font
  • Sharebar

    Semifluorinated alkane technology brings advantages for topical therapy

    Encouraging results with initial foray into development of treatments for dry eye disease

    Cincinnati, OH—Water-free vehicles based on semifluorinated alkane technology (EyeSol Platform Technology, Novaliq) have proven performance as an effective ocular lubricant and show promise for their ability to increase the solubility, stability, and bioavailability of topically delivered cyclosporine, said Edward J. Holland, MD.

    The ocular lubricant contains perfluorohexyloctane (F6H8) and is already commercially available in Europe as an over-the-counter product (EvoTears).

    Recent: Hypochlorous acid eyelid wash reduces bacterial load

    Currently, a phase II study is under way in the United States evaluating an investigational cyclosporine product (CyclASol, Novaliq) that formulates the immunomodulatory drug in the EyeSol Technology.

    “Topical administration remains the mainstay for treatment delivery in ophthalmology, but local side effects can affect treatment adherence, and that is particularly true with cyclosporine,” said Dr. Holland, director of cornea services, Cincinnati Eye Institute, Cincinnati, OH. “The EyeSol vehicle allows for a preservative-free, multidose preparation of cyclosporine, and importantly, it may improve its tolerability.”

    Related: Achieving physiologic restoration in dry eye

    Formulations based on the EyeSol Technology are clear, have a refractive index that is similar to water, and do not cause blurring of vision.

    Moreover, they do not require preservatives because they do not support microbial growth, and because they do not contain water, they eliminate the potential for hydrolytic reactions that cause drug degradation, said Michael O’Rourke, president, Scotia Vision Life Science Consultants, Tampa, FL.

    Clinical research

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results